Outcomes of a phase 2 trial for the inhaled JAK inhibitor, nezulcitinib, in hospitalized patients with acute lung injury due to severe COVID-19

Saggar, R.; Singh, D.; Moran, E.; Lombardi, D.; Nguyen, T.; Bourdet, D.; Pfeifer, N.; Woo, J.; Belperio, J.

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Outcomes of a phase 2 trial for the inhaled JAK inhibitor, nezulcitinib, in hospitalized patients with acute lung injury due to severe COVID-19

Saggar, R.; Singh, D.; Moran, E.; Lombardi, D.; Nguyen, T.; Bourdet, D.; Pfeifer, N.; Woo, J.; Belperio, J..

European Respiratory Journal ; 60, 2022.

Article in English | Web of Science | ID: covidwho-2310734

Fulltext

Print

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: Web of Science Type of study: Randomized controlled trials Language: English Journal: European Respiratory Journal Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

Print

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: Web of Science Type of study: Randomized controlled trials Language: English Journal: European Respiratory Journal Year: 2022 Document Type: Article